Follow
Michael I. Henderson
Title
Cited by
Cited by
Year
Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis–based cell and mice models
A Mukherjee, KD MacDonald, J Kim, MI Henderson, Y Eygeris, G Sahay
Science advances 6 (47), eabc5911, 2020
202020
Leveraging biological buffers for efficient messenger RNA delivery via lipid nanoparticles
MI Henderson, Y Eygeris, A Jozic, M Herrera, G Sahay
Molecular pharmaceutics 19 (11), 4275-4285, 2022
152022
Immune sensitization of melanoma to checkpoint inhibitor therapy using acoustically active nanoparticles
MI Henderson, L Xiang, S Drennan, X Yi, J Fischer, A Yildirim
Cancer Research 84 (6_Supplement), 5081-5081, 2024
2024
Quantifying lipid nanoparticle-mediated GFP expression in the murine retina.
A Curtis, M Henderson, Y Eygeris, W Tschetter, G Sahay, RC Ryals
Investigative Ophthalmology & Visual Science 64 (8), 5027-5027, 2023
2023
Studies Towards the Synthesis of Novel Oxadiazole Derivatives for Antibiotic Screening Against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa.
P Hewes, M Henderson
2021
Engineered mutant a-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models
M Henderson
2021
Liposomes vs Lipid Nanoparticle (LNP) Antibiotic Entrapment Efficiency Utilizing Fluorescein Dye
M Henderson
2021
The system can't perform the operation now. Try again later.
Articles 1–7